Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1 vs 6 Months of DAPT After Lower Extremity Endovascular Revascularization
NCT07076082Phase 4Recruiting
- Sponsor
- Corewell Health
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Corewell Health. Primary endpoints: Proportion of eligible patients offered study enrollment at 1 year, Proportion of eligible patients who consent to enrollment and randomization at 1 year and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT07076082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076082.